Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - The company is transitioning from being primarily known for Jakafi to becoming a high-growth business in hematology, oncology, and immunology [1][2] - The CEO emphasizes the strong organizational culture and the potential for meaningful product flow in the coming years [1] Hematology Focus - The company is concentrating on three key areas: hematology (specifically myeloproliferative neoplasms), solid tumor oncology, and immunology [2] - There is an opportunity to shift the hematology market from nonspecific symptomatic therapies to mutation-specific targeted therapies [2]